<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645788</url>
  </required_header>
  <id_info>
    <org_study_id>12429</org_study_id>
    <secondary_id>2008-008314-40</secondary_id>
    <nct_id>NCT00645788</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Inhaled Ciprofloxacin Compared to Placebo in Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between
      Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety issues are addressed in the Adverse Events section.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Day 28‑30</measure>
    <time_frame>Baseline and End of treatment (Day 28-30)</time_frame>
    <description>FEV1: The maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). This was recorded at the site using a spirometer. The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FEV1 at Visits 4, 5, and Follow-up Visits 8 and 9</measure>
    <time_frame>Baseline and Visit 4 (Day 7-9), Visit 5 (Day 14-16), Visit 8 (Day 41-45), and Visit 9 (Day 56 -60).</time_frame>
    <description>FEV1: The maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). This was recorded at the site using a spirometer. The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in P. Aeruginosa Density in the Sputum at Visits 4, 5, 7, 8 and 9</measure>
    <time_frame>Baseline and Visit 4 (Day 7-9), Visit 5 (Day 14-16), Visit 7 (Day 28-30), Visit 8 (Day 41-45), and Visit 9 (Day 56 -60).</time_frame>
    <description>Density of P. aeruginosa in the sputum is expressed as log10 of colony forming units (CFU)/gram (g). The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Pulmonary Exacerbation Requiring Intervention</measure>
    <time_frame>Up to visit 9 (Day 56-60)</time_frame>
    <description>Pulmonary exacerbations: Assessment of pulmonary exacerbation was conducted by the treating physician as part of the physical examination. Pulmonary exacerbation was defined by chest examination findings and any or all of the following symptoms: decreased exercise tolerance, increased cough, increased sputum/cough congestion, school or work absenteeism, increased adventitial sounds on the lung examination, and decreased appetite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC) at Visits 4, 5, 7, 8 and 9</measure>
    <time_frame>Baseline and Visit 4 (Day 7-9), Visit 5 (Day 14-16), Visit 7 (Day 28-30), Visit 8 (Day 41-45), and Visit 9 (Day 56 -60).</time_frame>
    <description>FVC: The maximal volume of air exhaled with maximally forced effort from a maximal inspiration, ie, vital capacity performed with a maximally forced expiratory effort expressed in liters at BTPS (body temperature and ambient pressure saturated with water vapor). The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Expiratory Flow (FEF 25-75%) at Visits 4, 5, 7, 8 and 9</measure>
    <time_frame>Baseline and Visit 4 (Day 7-9), Visit 5 (Day 14-16), Visit 7 (Day 28-30), Visit 8 (Day 41-45), and Visit 9 (Day 56 -60).</time_frame>
    <description>FEF 25-75% (also known as the maximum midexpiratory flow [MMEF]): The mean forced expiration flow over the middle half of the forced vital capacity (FVC). It was taken from the blow with the largest sum of FEV1 and FVC. The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing Ciprofloxacin-resistant Mucoid P.Aeruginosa Isolates</measure>
    <time_frame>Baseline and up to visit 9 (day 56-60)</time_frame>
    <description>Susceptibility and resistance assessment of a bacterial isolate was performed using the established Food and Drug Administration (FDA) susceptibility criteria for ciprofloxacin. The susceptibility criteria in mg/L are ≤1 for organisms Enterobacteriaciae, P. aeruginosa, Staphylococcus species and S. pneumoniae. The &quot;susceptible&quot; bacterial species likely responds to typical doses of ciprofloxacin. The resistance criteria for ciprofloxacin in mg/L are ≥4 mg/L for the same organisms. Resistance indicates that the bacteria is less likely to respond to typical doses of ciprofloxacin therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing Ciprofloxacin-resistant Non-mucoid P.Aeruginosa Isolates</measure>
    <time_frame>Baseline and up to visit 9 (day 56-60)</time_frame>
    <description>Susceptibility and resistance assessment of a bacterial isolate was performed using the established Food and Drug Administration (FDA) susceptibility criteria for ciprofloxacin. The susceptibility criteria in mg/L are ≤1 for organisms Enterobacteriaciae, P. aeruginosa, Staphylococcus species and S. pneumoniae. The &quot;susceptible&quot; bacterial species likely responds to typical doses of ciprofloxacin. The resistance criteria for ciprofloxacin in mg/L are ≥4 mg/L for the same organisms. Resistance indicates that the bacteria is less likely to respond to typical doses of ciprofloxacin therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Ciprofloxacin DPI Treatment on Quality of Life Measured by Cystic Fibrosis Quality of Life Questionnaire Revised (CFQ-R), Respiratory Scale</measure>
    <time_frame>Baseline and Visit 7 (Day 28-30) and Visit 9 (Day 56 -60)</time_frame>
    <description>The CF quality of life questionnaire revised (CFQ-R), a validated disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents and adults with cystic fibrosis (CF). It is self-administered and consists of 44 items, divided into 12 generic and disease-specific scales. The scale includes physical functioning, role, vitality, emotional functioning, social functioning, body image, eating disturbances, treatment burden, health perceptions, weight, respiratory symptoms, and digestive symptoms. Scale range: 0 to 100 (maximum). Better outcome with higher values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Ciprofloxacin From Selected Participants During Treatment</measure>
    <time_frame>Up to visit 7 (Day 28-30)</time_frame>
    <description>Plasma concentrations measured using validated high pressure liquid chromatography-mass specroscopy/mass spectroscopy (HPLC-MS/MS) methods in selected patients at predefined time windows to contribute pharmacokinetic (PK) information for an inter-study population PK evaluation. Sampling window for Plasma: Predose (trough level), &lt;15 min, 2.0 - 2.5 hour, and 4.0 - 7.0 hours after the end of inhalation. Number of samples vary at different time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum Concentrations of Ciprofloxacin From Selected Participants During Treatment</measure>
    <time_frame>Up to visit 7 (Day 28-30)</time_frame>
    <description>Sputum concentrations measured using validated HPLC-MS/MS methods in selected patients to contribute kinetic information for an inter-study population sputum kinetic evaluation. Number of samples vary at different time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Occurrence of Drug Induced Bronchospasms</measure>
    <time_frame>Up to visit 9 (Day 56-60)</time_frame>
    <description>Bronchospasm reported as adverse event: Bronchospasm defined as &gt;=15% drop in FEV1, and may also include allergic and excercise-induced bronchospasm. Drug-induced bronchospasm: Treatment-emergent bronchospasm was defined as &gt;=15% drop in FEV1 in the ITT/safety population. Note: One of the bronchospasm events was considered a serious adverse event, and it was not included under &quot;other&quot; adverse events. A sum of bronchospasm events was 1+6=7.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>32.50 mg Ciprofloxacin DPI (BAYQ3939)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32.50 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48.75 mg Ciprofloxacin DPI (BAYQ3939)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo for 32.50 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo for 48.75 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin (Cipro Inhale, BAYQ3939)</intervention_name>
    <description>32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days</description>
    <arm_group_label>32.50 mg Ciprofloxacin DPI (BAYQ3939)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg matching placebo powder formulation twice a day for 28 days</description>
    <arm_group_label>Matching Placebo for 32.50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin (Cipro Inhale, BAYQ3939)</intervention_name>
    <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)</description>
    <arm_group_label>48.75 mg Ciprofloxacin DPI (BAYQ3939)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)</description>
    <arm_group_label>Matching Placebo for 48.75 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects, or their legal representative(s), must have given their written informed
             consent to participate in the study after receiving adequate previous information and
             prior to any study specific procedures

          -  Children (12 - 17 years) or adults &gt;/=18 years

          -  Documented diagnosis Cystic Fibrosis (CF):

               -  documented sweat chloride &gt;/=60 mEq/L by quantitative pilocarpine iontophoresis
                  test (QPIT) or nasal potential difference

               -  either homozygous for ΔF508 genetic mutation or a compound heterozygous for 2
                  known CF mutations

               -  and clinical findings consistent with CF

          -  Chronic colonization with P. aeruginosa defined as a positive respiratory tract
             culture (sputum or throat swab) within 12 months prior to screening and at screening
             (Note: subjects with negative culture at screening can, at the discretion of the
             investigator, be rescreened at a later date)

          -  Ability to perform reproducible pulmonary function tests

          -  Ability to produce sputum (noninduced)

          -  Stable pulmonary status, FEV1 &gt;/=35% to &lt;/=75% (intraindividual variability +/-10% of
             absolute value). Note: The subject is not eligible for enrollment if the variability
             results in (or leads to) an FEV1 &lt;35%.

          -  Room air oximetry &gt;/=88% saturation

          -  Off antibiotics (except macrolide) and Cipro (oral) for at least 30 days prior to the
             administration of study drug for pulmonary exacerbation

          -  Stable regimen of standard CF treatment including chest physiotherapies and exercise
             regimens should not change during the 30 days prior to the administration of study
             drug and during the study (including macrolide administration unchanged in the
             previous 30 days)

          -  Subjects who are able to understand and follow instructions and who are able to
             participate in the study for the entire period

          -  Women who are willing to use an adequate method of contraception for 3 months after
             receiving the study drug. Adequate methods of contraception include vasectomy or
             condom use by their partners, diaphragm with spermicidal gel, coil (intrauterine
             device), surgical sterilization or oral contraceptive

        Exclusion Criteria:

          -  Findings on screening history and physical examination unrelated to CF that could
             potentially affect the efficacy measurements (eg, chest surgery)

          -  Subjects with colonization of Pseudomonas aeruginosa and a CIPRO MIC of &gt;/=256 µg/ml
             or mg/l

          -  Burkholderia cepacia complex colonization of their respiratory tract within the past
             12 months (documented by screen laboratory)

          -  Known aspergillosis (unless asymptomatic). Patients with invasive disease, ABPA with
             IGE &gt; 500 mg/dL will be excluded

          -  Transaminase level &gt;3x upper limit of normal (ULN)

          -  Massive hemoptysis (&gt;/=300 cc or requiring blood transfusion) in the preceding 4 weeks

          -  Intravenous antibiotic treatment for pulmonary exacerbation in the past 30 days

          -  Subjects with a medical disorder, condition or history of such that would impair the
             subject's ability to participate or complete this study in the opinion of the
             investigator or the sponsor

          -  Febrile illness within 1 week before the start of the study

          -  Active treatment for nontuberculosis mycobacteria

          -  Exposure to any investigational drug within 30 days

          -  Any history of allergic reaction to fluoroquinolones or other quinolones

          -  On oral steroids &gt;20 mg/day for longer than 14 days in the past 3 months

          -  Creatinine &gt;/=2x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123-4282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912-4005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa city</city>
        <state>Iowa</state>
        <zip>52242-1089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerville</city>
        <state>New Jersey</state>
        <zip>08876</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308-1062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB3 8RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <state>North Ireland</state>
        <zip>BT12 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <results_first_submitted>January 21, 2012</results_first_submitted>
  <results_first_submitted_qc>May 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2012</results_first_posted>
  <last_update_submitted>May 30, 2014</last_update_submitted>
  <last_update_submitted_qc>May 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ciprofloxacin</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>sweat test</keyword>
  <keyword>pulmonary function test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first visit of the first subject was on 05 May 2008 and the last visit of the last subject on 25 Jan 2011. This study was conducted at 73 centers from 8 countries.</recruitment_details>
      <pre_assignment_details>Of all enrolled 486 subjects, 188 had screening failures, the remaining 288 were randomized but 2 subjects (one each in 32.5 mg Ciprofloxacin DPI (Dry Powder for Inhalation) and 48.75 mg Ciprofloxacin DPI groups) did not receive any study drug. A total of 286 subjects received one of the 4 study drug treatments.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
          <description>32.50 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
        </group>
        <group group_id="P2">
          <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
          <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
        </group>
        <group group_id="P3">
          <title>Matching Placebo for 32.50 mg</title>
          <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
        </group>
        <group group_id="P4">
          <title>Matching Placebo for 48.75 mg</title>
          <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Receive Treatment</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pulmonary exacerbation</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
          <description>32.50 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
        </group>
        <group group_id="B2">
          <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
          <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
        </group>
        <group group_id="B3">
          <title>Matching Placebo for 32.50 mg</title>
          <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
        </group>
        <group group_id="B4">
          <title>Matching Placebo for 48.75 mg</title>
          <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="65"/>
            <count group_id="B4" value="35"/>
            <count group_id="B5" value="286"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="9.3"/>
                    <measurement group_id="B2" value="29.3" spread="9.5"/>
                    <measurement group_id="B3" value="31.7" spread="12.1"/>
                    <measurement group_id="B4" value="29.1" spread="9.4"/>
                    <measurement group_id="B5" value="29.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume in 1 second (FEV1)</title>
          <units>Percentage of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="11.3"/>
                    <measurement group_id="B2" value="54.7" spread="12.3"/>
                    <measurement group_id="B3" value="54.8" spread="10.6"/>
                    <measurement group_id="B4" value="52.7" spread="10.7"/>
                    <measurement group_id="B5" value="54.6" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Day 28‑30</title>
        <description>FEV1: The maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). This was recorded at the site using a spirometer. The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
        <time_frame>Baseline and End of treatment (Day 28-30)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo for 32.50 mg</title>
            <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo for 48.75 mg</title>
            <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Day 28‑30</title>
          <description>FEV1: The maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). This was recorded at the site using a spirometer. The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
          <population>Intent to treat</population>
          <units>Percent of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="6.01"/>
                    <measurement group_id="O2" value="-0.62" spread="5.52"/>
                    <measurement group_id="O3" value="-2.2" spread="5.47"/>
                    <measurement group_id="O4" value="-2.2" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ho: |Cipro 32.5 mg - matching placebo|=0 and |Cipro 48.75 mg - matching placebo|=0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FEV1 at Visits 4, 5, and Follow-up Visits 8 and 9</title>
        <description>FEV1: The maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). This was recorded at the site using a spirometer. The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
        <time_frame>Baseline and Visit 4 (Day 7-9), Visit 5 (Day 14-16), Visit 8 (Day 41-45), and Visit 9 (Day 56 -60).</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo for 32.50 mg</title>
            <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo for 48.75 mg</title>
            <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1 at Visits 4, 5, and Follow-up Visits 8 and 9</title>
          <description>FEV1: The maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). This was recorded at the site using a spirometer. The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
          <population>Intent to treat</population>
          <units>Percent of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="5.14"/>
                    <measurement group_id="O2" value="0.65" spread="4.62"/>
                    <measurement group_id="O3" value="-0.84" spread="3.92"/>
                    <measurement group_id="O4" value="-0.36" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="6.14"/>
                    <measurement group_id="O2" value="0.26" spread="3.94"/>
                    <measurement group_id="O3" value="-1.6" spread="3.59"/>
                    <measurement group_id="O4" value="-0.87" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="5.95"/>
                    <measurement group_id="O2" value="-0.71" spread="5.14"/>
                    <measurement group_id="O3" value="-1.2" spread="6.04"/>
                    <measurement group_id="O4" value="-1.6" spread="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="5.22"/>
                    <measurement group_id="O2" value="-0.95" spread="5.29"/>
                    <measurement group_id="O3" value="-1.9" spread="4.89"/>
                    <measurement group_id="O4" value="-1.6" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in P. Aeruginosa Density in the Sputum at Visits 4, 5, 7, 8 and 9</title>
        <description>Density of P. aeruginosa in the sputum is expressed as log10 of colony forming units (CFU)/gram (g). The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
        <time_frame>Baseline and Visit 4 (Day 7-9), Visit 5 (Day 14-16), Visit 7 (Day 28-30), Visit 8 (Day 41-45), and Visit 9 (Day 56 -60).</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo for 32.50 mg</title>
            <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo for 48.75 mg</title>
            <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in P. Aeruginosa Density in the Sputum at Visits 4, 5, 7, 8 and 9</title>
          <description>Density of P. aeruginosa in the sputum is expressed as log10 of colony forming units (CFU)/gram (g). The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
          <population>Intent to treat</population>
          <units>log10(cfu/g)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="2.21"/>
                    <measurement group_id="O2" value="-1.1" spread="1.63"/>
                    <measurement group_id="O3" value="-0.35" spread="2.09"/>
                    <measurement group_id="O4" value="-0.56" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="2.51"/>
                    <measurement group_id="O2" value="-1.0" spread="2.13"/>
                    <measurement group_id="O3" value="0.15" spread="2.06"/>
                    <measurement group_id="O4" value="-0.65" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="2.57"/>
                    <measurement group_id="O2" value="-0.78" spread="2.54"/>
                    <measurement group_id="O3" value="-0.07" spread="2.59"/>
                    <measurement group_id="O4" value="-0.63" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="2.52"/>
                    <measurement group_id="O2" value="-0.11" spread="2.39"/>
                    <measurement group_id="O3" value="-0.14" spread="2.21"/>
                    <measurement group_id="O4" value="-0.00" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="2.19"/>
                    <measurement group_id="O2" value="-0.16" spread="2.26"/>
                    <measurement group_id="O3" value="-0.19" spread="2.15"/>
                    <measurement group_id="O4" value="0.54" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At visit 7 (End of treatment) Ho: |Cipro 32.5 - matching placebo| =0 and
|Cipro 48.75 - matching placebo| =0</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Pulmonary Exacerbation Requiring Intervention</title>
        <description>Pulmonary exacerbations: Assessment of pulmonary exacerbation was conducted by the treating physician as part of the physical examination. Pulmonary exacerbation was defined by chest examination findings and any or all of the following symptoms: decreased exercise tolerance, increased cough, increased sputum/cough congestion, school or work absenteeism, increased adventitial sounds on the lung examination, and decreased appetite.</description>
        <time_frame>Up to visit 9 (Day 56-60)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo for 32.50 mg</title>
            <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo for 48.75 mg</title>
            <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Pulmonary Exacerbation Requiring Intervention</title>
          <description>Pulmonary exacerbations: Assessment of pulmonary exacerbation was conducted by the treating physician as part of the physical examination. Pulmonary exacerbation was defined by chest examination findings and any or all of the following symptoms: decreased exercise tolerance, increased cough, increased sputum/cough congestion, school or work absenteeism, increased adventitial sounds on the lung examination, and decreased appetite.</description>
          <population>Intent to treat</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">only 16.1 percent of patients had an exacerbation</measurement>
                    <measurement group_id="O2" value="NA">only 17.2 percent of patients had an exacerbation</measurement>
                    <measurement group_id="O3" value="NA">only 20.0 percent of patients had an exacerbation</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="43">only 28.6 percent of patients had an exacerbation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Vital Capacity (FVC) at Visits 4, 5, 7, 8 and 9</title>
        <description>FVC: The maximal volume of air exhaled with maximally forced effort from a maximal inspiration, ie, vital capacity performed with a maximally forced expiratory effort expressed in liters at BTPS (body temperature and ambient pressure saturated with water vapor). The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
        <time_frame>Baseline and Visit 4 (Day 7-9), Visit 5 (Day 14-16), Visit 7 (Day 28-30), Visit 8 (Day 41-45), and Visit 9 (Day 56 -60).</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo for 32.50 mg</title>
            <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo for 48.75 mg</title>
            <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity (FVC) at Visits 4, 5, 7, 8 and 9</title>
          <description>FVC: The maximal volume of air exhaled with maximally forced effort from a maximal inspiration, ie, vital capacity performed with a maximally forced expiratory effort expressed in liters at BTPS (body temperature and ambient pressure saturated with water vapor). The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
          <population>Intent to treat</population>
          <units>Percent of predicted FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="8.97"/>
                    <measurement group_id="O2" value="0.22" spread="5.07"/>
                    <measurement group_id="O3" value="-0.94" spread="5.23"/>
                    <measurement group_id="O4" value="-0.45" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="9.78"/>
                    <measurement group_id="O2" value="-0.48" spread="5.11"/>
                    <measurement group_id="O3" value="-1.8" spread="4.51"/>
                    <measurement group_id="O4" value="-1.1" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="8.91"/>
                    <measurement group_id="O2" value="-1.4" spread="6.04"/>
                    <measurement group_id="O3" value="-2.7" spread="6.97"/>
                    <measurement group_id="O4" value="-1.4" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="8.62"/>
                    <measurement group_id="O2" value="-0.65" spread="6.44"/>
                    <measurement group_id="O3" value="-1.6" spread="7.31"/>
                    <measurement group_id="O4" value="0.13" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="8.54"/>
                    <measurement group_id="O2" value="-0.70" spread="6.64"/>
                    <measurement group_id="O3" value="-2.3" spread="5.63"/>
                    <measurement group_id="O4" value="-0.53" spread="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Expiratory Flow (FEF 25-75%) at Visits 4, 5, 7, 8 and 9</title>
        <description>FEF 25-75% (also known as the maximum midexpiratory flow [MMEF]): The mean forced expiration flow over the middle half of the forced vital capacity (FVC). It was taken from the blow with the largest sum of FEV1 and FVC. The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
        <time_frame>Baseline and Visit 4 (Day 7-9), Visit 5 (Day 14-16), Visit 7 (Day 28-30), Visit 8 (Day 41-45), and Visit 9 (Day 56 -60).</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo for 32.50 mg</title>
            <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo for 48.75 mg</title>
            <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Flow (FEF 25-75%) at Visits 4, 5, 7, 8 and 9</title>
          <description>FEF 25-75% (also known as the maximum midexpiratory flow [MMEF]): The mean forced expiration flow over the middle half of the forced vital capacity (FVC). It was taken from the blow with the largest sum of FEV1 and FVC. The later time point minus baseline, days as planned and the last observation carried forward (LOCF) used.</description>
          <population>Intent to treat</population>
          <units>Percent of predicted FEF 25-75%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="7.12"/>
                    <measurement group_id="O2" value="1.09" spread="6.90"/>
                    <measurement group_id="O3" value="-1.0" spread="4.65"/>
                    <measurement group_id="O4" value="-0.49" spread="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="8.16"/>
                    <measurement group_id="O2" value="0.95" spread="4.73"/>
                    <measurement group_id="O3" value="-1.1" spread="4.49"/>
                    <measurement group_id="O4" value="-0.89" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="6.84"/>
                    <measurement group_id="O2" value="0.35" spread="5.39"/>
                    <measurement group_id="O3" value="-2.1" spread="5.62"/>
                    <measurement group_id="O4" value="-1.8" spread="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="7.56"/>
                    <measurement group_id="O2" value="-0.33" spread="5.19"/>
                    <measurement group_id="O3" value="-1.2" spread="6.23"/>
                    <measurement group_id="O4" value="-1.9" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="7.35"/>
                    <measurement group_id="O2" value="-0.49" spread="5.55"/>
                    <measurement group_id="O3" value="-1.3" spread="5.63"/>
                    <measurement group_id="O4" value="-1.4" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Developing Ciprofloxacin-resistant Mucoid P.Aeruginosa Isolates</title>
        <description>Susceptibility and resistance assessment of a bacterial isolate was performed using the established Food and Drug Administration (FDA) susceptibility criteria for ciprofloxacin. The susceptibility criteria in mg/L are ≤1 for organisms Enterobacteriaciae, P. aeruginosa, Staphylococcus species and S. pneumoniae. The “susceptible” bacterial species likely responds to typical doses of ciprofloxacin. The resistance criteria for ciprofloxacin in mg/L are ≥4 mg/L for the same organisms. Resistance indicates that the bacteria is less likely to respond to typical doses of ciprofloxacin therapy.</description>
        <time_frame>Baseline and up to visit 9 (day 56-60)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo for 32.50 mg</title>
            <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo for 48.75 mg</title>
            <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing Ciprofloxacin-resistant Mucoid P.Aeruginosa Isolates</title>
          <description>Susceptibility and resistance assessment of a bacterial isolate was performed using the established Food and Drug Administration (FDA) susceptibility criteria for ciprofloxacin. The susceptibility criteria in mg/L are ≤1 for organisms Enterobacteriaciae, P. aeruginosa, Staphylococcus species and S. pneumoniae. The “susceptible” bacterial species likely responds to typical doses of ciprofloxacin. The resistance criteria for ciprofloxacin in mg/L are ≥4 mg/L for the same organisms. Resistance indicates that the bacteria is less likely to respond to typical doses of ciprofloxacin therapy.</description>
          <population>Intent to treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P.aeruginosa sensitive - baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P.aeruginosa resistant - up to visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Developing Ciprofloxacin-resistant Non-mucoid P.Aeruginosa Isolates</title>
        <description>Susceptibility and resistance assessment of a bacterial isolate was performed using the established Food and Drug Administration (FDA) susceptibility criteria for ciprofloxacin. The susceptibility criteria in mg/L are ≤1 for organisms Enterobacteriaciae, P. aeruginosa, Staphylococcus species and S. pneumoniae. The “susceptible” bacterial species likely responds to typical doses of ciprofloxacin. The resistance criteria for ciprofloxacin in mg/L are ≥4 mg/L for the same organisms. Resistance indicates that the bacteria is less likely to respond to typical doses of ciprofloxacin therapy.</description>
        <time_frame>Baseline and up to visit 9 (day 56-60)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo for 32.50 mg</title>
            <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo for 48.75 mg</title>
            <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing Ciprofloxacin-resistant Non-mucoid P.Aeruginosa Isolates</title>
          <description>Susceptibility and resistance assessment of a bacterial isolate was performed using the established Food and Drug Administration (FDA) susceptibility criteria for ciprofloxacin. The susceptibility criteria in mg/L are ≤1 for organisms Enterobacteriaciae, P. aeruginosa, Staphylococcus species and S. pneumoniae. The “susceptible” bacterial species likely responds to typical doses of ciprofloxacin. The resistance criteria for ciprofloxacin in mg/L are ≥4 mg/L for the same organisms. Resistance indicates that the bacteria is less likely to respond to typical doses of ciprofloxacin therapy.</description>
          <population>Intent to treat</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P.aeruginosa sensitive - baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P.aeruginosa resistant- up to visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Ciprofloxacin DPI Treatment on Quality of Life Measured by Cystic Fibrosis Quality of Life Questionnaire Revised (CFQ-R), Respiratory Scale</title>
        <description>The CF quality of life questionnaire revised (CFQ-R), a validated disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents and adults with cystic fibrosis (CF). It is self-administered and consists of 44 items, divided into 12 generic and disease-specific scales. The scale includes physical functioning, role, vitality, emotional functioning, social functioning, body image, eating disturbances, treatment burden, health perceptions, weight, respiratory symptoms, and digestive symptoms. Scale range: 0 to 100 (maximum). Better outcome with higher values.</description>
        <time_frame>Baseline and Visit 7 (Day 28-30) and Visit 9 (Day 56 -60)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo for 32.50 mg</title>
            <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo for 48.75 mg</title>
            <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Ciprofloxacin DPI Treatment on Quality of Life Measured by Cystic Fibrosis Quality of Life Questionnaire Revised (CFQ-R), Respiratory Scale</title>
          <description>The CF quality of life questionnaire revised (CFQ-R), a validated disease-specific instrument that measures health-related quality of life (HRQOL) for adolescents and adults with cystic fibrosis (CF). It is self-administered and consists of 44 items, divided into 12 generic and disease-specific scales. The scale includes physical functioning, role, vitality, emotional functioning, social functioning, body image, eating disturbances, treatment burden, health perceptions, weight, respiratory symptoms, and digestive symptoms. Scale range: 0 to 100 (maximum). Better outcome with higher values.</description>
          <population>Intent to treat</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" spread="18.7"/>
                    <measurement group_id="O2" value="59.5" spread="19.0"/>
                    <measurement group_id="O3" value="61.3" spread="18.6"/>
                    <measurement group_id="O4" value="68.3" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" spread="15.9"/>
                    <measurement group_id="O2" value="60.0" spread="19.7"/>
                    <measurement group_id="O3" value="58.9" spread="18.7"/>
                    <measurement group_id="O4" value="61.6" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="18.9"/>
                    <measurement group_id="O2" value="60.6" spread="20.5"/>
                    <measurement group_id="O3" value="61.1" spread="19.8"/>
                    <measurement group_id="O4" value="71.2" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of Ciprofloxacin From Selected Participants During Treatment</title>
        <description>Plasma concentrations measured using validated high pressure liquid chromatography-mass specroscopy/mass spectroscopy (HPLC-MS/MS) methods in selected patients at predefined time windows to contribute pharmacokinetic (PK) information for an inter-study population PK evaluation. Sampling window for Plasma: Predose (trough level), &lt;15 min, 2.0 - 2.5 hour, and 4.0 - 7.0 hours after the end of inhalation. Number of samples vary at different time points.</description>
        <time_frame>Up to visit 7 (Day 28-30)</time_frame>
        <population>Analysis was not performed due to insufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentrations of Ciprofloxacin From Selected Participants During Treatment</title>
          <description>Plasma concentrations measured using validated high pressure liquid chromatography-mass specroscopy/mass spectroscopy (HPLC-MS/MS) methods in selected patients at predefined time windows to contribute pharmacokinetic (PK) information for an inter-study population PK evaluation. Sampling window for Plasma: Predose (trough level), &lt;15 min, 2.0 - 2.5 hour, and 4.0 - 7.0 hours after the end of inhalation. Number of samples vary at different time points.</description>
          <population>Analysis was not performed due to insufficient data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sputum Concentrations of Ciprofloxacin From Selected Participants During Treatment</title>
        <description>Sputum concentrations measured using validated HPLC-MS/MS methods in selected patients to contribute kinetic information for an inter-study population sputum kinetic evaluation. Number of samples vary at different time points.</description>
        <time_frame>Up to visit 7 (Day 28-30)</time_frame>
        <population>Analysis was not performed due to insufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Sputum Concentrations of Ciprofloxacin From Selected Participants During Treatment</title>
          <description>Sputum concentrations measured using validated HPLC-MS/MS methods in selected patients to contribute kinetic information for an inter-study population sputum kinetic evaluation. Number of samples vary at different time points.</description>
          <population>Analysis was not performed due to insufficient data.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Occurrence of Drug Induced Bronchospasms</title>
        <description>Bronchospasm reported as adverse event: Bronchospasm defined as &gt;=15% drop in FEV1, and may also include allergic and excercise-induced bronchospasm. Drug-induced bronchospasm: Treatment-emergent bronchospasm was defined as &gt;=15% drop in FEV1 in the ITT/safety population. Note: One of the bronchospasm events was considered a serious adverse event, and it was not included under &quot;other&quot; adverse events. A sum of bronchospasm events was 1+6=7.</description>
        <time_frame>Up to visit 9 (Day 56-60)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O2">
            <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
            <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo for 32.50 mg</title>
            <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
          <group group_id="O4">
            <title>Matching Placebo for 48.75 mg</title>
            <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Occurrence of Drug Induced Bronchospasms</title>
          <description>Bronchospasm reported as adverse event: Bronchospasm defined as &gt;=15% drop in FEV1, and may also include allergic and excercise-induced bronchospasm. Drug-induced bronchospasm: Treatment-emergent bronchospasm was defined as &gt;=15% drop in FEV1 in the ITT/safety population. Note: One of the bronchospasm events was considered a serious adverse event, and it was not included under &quot;other&quot; adverse events. A sum of bronchospasm events was 1+6=7.</description>
          <population>Intent to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reported as Adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Defined as &gt;=15 percent drop in FEV1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>32.50 mg Ciprofloxacin DPI (BAYQ3939)</title>
          <description>32.5 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
        </group>
        <group group_id="E2">
          <title>48.75 mg Ciprofloxacin DPI (BAYQ3939)</title>
          <description>48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days</description>
        </group>
        <group group_id="E3">
          <title>Matching Placebo for 32.50 mg</title>
          <description>Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days</description>
        </group>
        <group group_id="E4">
          <title>Matching Placebo for 48.75 mg</title>
          <description>Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Distal intestinal obstruction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Product taste abnormal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The agreed point of publication is 12-18 months after database lock at the earliest. Bayer will have 30-45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable). No publication of single center data should be done prior of publication if multi-center data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

